Previous Close | 5.53 |
Open | 6.75 |
Bid | 4.05 |
Ask | 7.80 |
Strike | 47.00 |
Expire Date | 2024-05-31 |
Day's Range | 6.45 - 6.75 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
PRINCETON, N.J., June 01, 2024--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
Bristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the first-line treatment of unresectable or metastatic urothelial carcinoma.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.